Shanghai Fosun Pharmaceutical Group CO Ltd (OP:SFOSF)

2.200 UNCHANGED

Last Price Updated: 2:49 PM EDT, Aug 19, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	2.200
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	2.200
Today's Range	2.200 - 2.200
52wk Range	1.950 - 3.500
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion

September 06, 2026

From Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Via ACN Newswire

Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO ↗

June 10, 2023

HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and...

Via Talk Markets

Performance

YTD	-20.9%	-20.9%
1 Month	+12.8%	+12.8%
3 Month	+8.9%	+8.9%
6 Month	-9.7%	-9.7%
1 Year	-30.2%	-30.2%

More News

Is Ardelyx is A Buy After Slip in Early 2022

November 21, 2022

Via MarketBeat

Frequently Asked Questions

Is Shanghai Fosun Pharmaceutical Group CO Ltd publicly traded?

Yes, Shanghai Fosun Pharmaceutical Group CO Ltd is publicly traded.

What exchange does Shanghai Fosun Pharmaceutical Group CO Ltd trade on?

Shanghai Fosun Pharmaceutical Group CO Ltd trades on the OTC Traded

What is the ticker symbol for Shanghai Fosun Pharmaceutical Group CO Ltd?

The ticker symbol for Shanghai Fosun Pharmaceutical Group CO Ltd is SFOSF on the OTC Traded

What is the current price of Shanghai Fosun Pharmaceutical Group CO Ltd?

The current price of Shanghai Fosun Pharmaceutical Group CO Ltd is 2.200

When was Shanghai Fosun Pharmaceutical Group CO Ltd last traded?

The last trade of Shanghai Fosun Pharmaceutical Group CO Ltd was at 08/19/26 02:49 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.